Merck & Co. Inc.'s PD-1 inhibitor Keytruda (pembrolizumab) as a monotherapy is likely to get a more modest slice of the first-line lung cancer pie than some hoped for, following the release of detailed data from the first-line KEYNOTE-042 study on June 3 at the American Society of Clinical Oncology meeting.
The KEYNOTE-042 study tested Keytruda as a monotherapy against combination chemotherapy in 1,274 patients with first-line non-small cell lung cancer...






